SWOG clinical trial number
SWOG-8719
Evaluations of Didemnin B or Ifosfamide/Mesna in Endocrine Resistant Prostate Cancer and of Ifosfamide/Mesna in Patients without Prior Endocrine Manipulation
Closed
Phase
Accrual
87%
Published
Abbreviated Title
Evaluations of Didemnin B or Ifosfamide/Mesna in Endocrine Resistant Prostate Cancer and of Ifosfamide/Mesna in Patients without Prior Endocrine Manipulation
Activated
11/01/1988
Closed
05/15/1993
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1996
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.
1995
Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.
1994
Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase